ABSTRACT:The P-glycoprotein (P-gp)-deficient mouse model is used to assess the influence of P-gp-mediated efflux on the central nervous system ( The efflux transporter P-glycoprotein (P-gp) attenuates the central nervous system (CNS) distribution of many drugs, including opioids, triptans, protease inhibitors, and antihistamines. One method used to assess the influence of P-gp on the CNS distribution of compounds is the P-gp-deficient mouse model. The P-gp efflux ratio, calculated from the ratio of brain/plasma partition coefficient (K p,brain ) in P-gpdeficient (mdr1aϪ/Ϫ) mice to K p,brain in P-gp-competent (mdr1aϩ/ϩ) mice, reflects the degree to which P-gp-mediated efflux attenuates CNS distribution. However, when other processes influence CNS distribution, the P-gp efflux ratio may be a poor indicator of the degree to which CNS distribution of a compound is impaired.